title: Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.
abstract: Despite the lack of placebo-controlled trials, glucocorticoids are considered the mainstay of initial treatment for idiopathic inflammatory myopathy and myositis-associated interstitial lung disease. Glucocorticoid-sparing agents are often given concomitantly with other immunosuppressive agents, particularly in patients with moderate or severe disease. First-line conventional immunosuppressive drugs include either methotrexate or azathioprine, and when they fail, more aggressive therapy includes mycophenolate mofetil, tacrolimus or cyclosporine, intravenous immunoglobulin, rituximab, or cyclophosphamide, used alone or in various combinations. Further investigations are required to assess the role of more novel therapies in the treatment of myositis and myositis-associated interstitial lung disease.
authors: a Department of Medicine, Myositis Center and Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
authors: Siamak
authors: S
authors: Moghadam-Kia
authors: a Department of Medicine, Myositis Center and Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
authors: Rohit
authors: R
authors: Aggarwal
authors: Chester V
authors: CV
authors: Oddis
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D017563:Lung Diseases, Interstitial / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology*; D009187:Myelitis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*; D012720:Severity of Illness Index
chemical_list: D007166:Immunosuppressive Agents
keywords: dermatomyositis; idiopathic inflammatory myopathy; myositis; polymyositis; treatment